Identification of peptidomimetic telomere dysfunction inhibitor (TELODIN) through telomere dysfunction-induced foci (TIF) assay

Lihui Wang; Zhiguo Wang; Jun-Ping Liu

doi:10.1016/j.xpro.2021.100620

Identification of peptidomimetic telomere dysfunction inhibitor (TELODIN) through telomere dysfunction-induced foci (TIF) assay

STAR Protoc. 2021 Jun 19;2(3):100620. doi: 10.1016/j.xpro.2021.100620. eCollection 2021 Sep 17.

Authors

Lihui Wang¹, Zhiguo Wang¹, Jun-Ping Liu^{1

2

3

4}

Affiliations

¹ Institute of Ageing Research, Hangzhou Normal University School of Medicine, Hangzhou, Zhejiang Province 311121, China.
² Hangzhou Duanli Biotechnology Company Limited, Hangzhou, Zhejiang Province 311121, China.
³ Department of Immunology, Monash University Faculty of Medicine, Prahran, VIC 3181, Australia.
⁴ Hudson Institute of Medical Research, and Monash University Department of Molecular and Translational Science, Clayton, VIC 3168, Australia.

Abstract

Telomere dysfunction-induced focus (TIF) assay allows efficient profiling of telomere dysfunctions in cells and tissues. Here, we describe the use of the TIF assay to screen synthetic peptides from E3 ubiquitin ligase FBW7, a tumor suppressor gene product, to prevent TIFs caused by environmental radiation stress. We demonstrate peptidomimetic telomere dysfunction inhibitor as a potentially intervening therapeutic drug candidate in aging-related diseases. This work demonstrates a novel utility of the TIF assay protocol in identifying telomere dysfunction inhibitors. For complete details on the use and execution of this protocol, please refer to Wang et al (2020).

Keywords: Cancer; Cell Biology; Cell culture; Cell-based Assays; Microscopy; Molecular Biology; Molecular/Chemical Probes; Protein Biochemistry.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cells, Cultured
Humans
Peptidomimetics*
Telomere / drug effects*

Substances

Peptidomimetics